DSM Panel Members Still Getting Pharma Funds
Despite promises to cut back on Pharma funds, 56% of DSM V panel members have reported industry ties— Zero improvement over the percent of DSM-IV members.
Monthly Archives: May 2010
American Psychiatric Association Called Upon to Cut Drug Company Ties and Put Lives of Children Before Profits
As psychiatrists from around the world flood the area this weekend to take part in the Annual Meeting of the American Psychiatric Association (APA), psychiatric watchdog Citizens Commission on Human Rights (CCHR) is demanding that the APA sever all ties to pharmaceutical company interests and that psychiatrists stop killing children with harmful drugs.
Meet the Psychiatrist Pushing For A Brave New World of Pre-Drugging Kids—Patrick McGorry
One of the most controversial proposed disorders for the upcoming revision of psychiatry’s billing bible of mental disorders, (the DSM-5) is Psychosis Risk Syndrome (PRS) a “mental disorder” that, if voted into DSM, would confirm the allegations that psychiatry is manufacturing a Brave New World for itself—heavily backed by Big Pharma—of drugging children before they develop a “mental illness.”
Does anyone else think this is outrageous? “Glaxo Is Testing Paxil on 7-Year-Olds Despite Well Known Suicide Risks”
It was established years ago that Paxil carries a risk of suicide in children and teens, but GlaxoSmithKline (GSK) has for the last 18 months been conducting a study of the antidepressant in kids as young as seven — in Japan. It’s not clear why the company would want to draw more attention to its already controversial pill, but it appears as if GSK might be hoping to see a reduced suicide risk in a small population of users — a result the company could use to cast doubt on the Paxil-equals-teen-suicide meme that dominates discussion of the drug.
Australia’s growing drug problem—Elderly overprescribed antidepressants
Older Australians are being overprescribed medications for depression, according to a study by University of Queensland researchers published today in the Australian and New Zealand Journal of Psychiatry.